Business 4 min read By Callum Montgomery
Elizabeth Holmes returns to the spotlight, but the Theranos lesson is still about governance
A24 documentary You Can See Everything has revived public fascination with Elizabeth Holmes. For business readers, the more durable story is how founder mythology, weak challenge and reputation management can outlive the company that created them.
Elizabeth Holmes is once again commanding attention, this time through a documentary rather than a courtroom. A24’s You Can See Everything has premiered at Telluride, giving filmmakers Nathan Fielder and Lance Oppenheim unusually close access to the Theranos founder in the final 34 days before she entered federal prison.
The teaser alone generated more than two million YouTube views in about a day, according to ABC. That level of interest says something about Holmes’s continued cultural power. It also shows why the Theranos case remains relevant to business long after the company disappeared.
Holmes was convicted in 2022 of defrauding investors and is serving a federal sentence in Texas. Yet her public image remains valuable enough to anchor a major A24 release. The business lesson is uncomfortable: reputation does not simply vanish when an enterprise collapses. A founder can remain a recognizable media asset even after the organization associated with the name has become a case study in failure.
That creates a second life for corporate mythology. During Theranos’s rise, Holmes was presented as a transformational entrepreneur who could remake blood testing. The company attracted investors, political figures and prominent supporters. Its story depended not only on a claimed technology but on confidence in the founder’s ability to embody an inevitable future.
When the claims fell apart, the narrative reversed. The visionary became a warning. But the structure remained personality-centered. Holmes continued to dominate the story, sometimes at the expense of a less glamorous question: why did so many institutions fail to demand stronger evidence before granting credibility, capital and influence?
You Can See Everything appears to understand that tension. It follows Holmes during the final weeks before prison and continues into the incarceration period. Holmes participated in the project, which means viewers will inevitably debate whether the film offers accountability, self-presentation or both.
For executives and investors, that debate mirrors a familiar governance problem. Access is not the same as transparency. A charismatic leader can provide enormous quantities of information while still controlling what matters: framing, sequence, emotion and the assumptions through which audiences interpret facts.
The Theranos story remains useful because it exposes the limits of founder-centric diligence. Investors do not only need compelling presentations and elite endorsements. They need technical validation, independent challenge, functional boards and a culture in which uncomfortable questions can survive contact with a powerful chief executive.
The film’s Telluride premiere was kept unusually secret, which amplified its launch. That is effective marketing, but it also fits the subject. Holmes’s public life has repeatedly blurred the boundary between a business story and a story about narrative control.
A24 lists the documentary among its 2026 releases, with reporting indicating a theatrical release planned for October. Its commercial performance will show how much demand remains for another telling of a scandal that has already produced books, podcasts, documentaries and television drama.
The more important test is what audiences take from it. If the story becomes only another study of Holmes’s personality, the institutional lessons risk fading again. Theranos was not built by one person’s charisma alone. It was enabled by systems that rewarded confidence before evidence. Those systems are still part of modern startup culture, which is why a documentary about the last month before prison can still matter to boardrooms years later.
